QIAGEN News | finanzen.ch

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

03.11.22	EQS-DD: Qiagen N.V.: Dr. Metin Colpan, Release of 457 Restricted Stock Units based on grant made on October 31, 2012. Exercise Price: $0.00. Closing price on October 31, 2022: $43.56. Subsequent ... (EQS Group)
02.11.22	EQS-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
02.11.22	EQS-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
02.11.22	EQS-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
02.11.22	EQS-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
28.10.22	EQS-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
25.10.22	EQS-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
21.10.22	EQS-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
17.10.22	EQS-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
17.10.22	EQS-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
11.10.22	Bio-Rad Laboratories In Talks To Merge With Qiagen : Report (RTTNews)
07.10.22	EQS-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
07.10.22	EQS-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
14.09.22	Neuron23 and QIAGEN Announce Collaboration to Develop the First Next-Generation Sequencing Companion Diagnostic for Novel Parkinson's Disease Drug (PR Newswire)
24.08.22	DGAP-AFR: Qiagen N.V.: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] (EQS Group)
24.08.22	DGAP-AFR: Qiagen N.V.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG (EQS Group)
29.07.22	DGAP-CMS: QIAGEN N.V.: Release of a capital market information (EQS Group)
27.07.22	Qiagen Raises FY Outlook (RTTNews)
10.06.22	DGAP-DD: QIAGEN N.V. english (EQS Group)
08.06.22	DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
01.06.22	DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
01.06.22	DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
27.05.22	DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
27.05.22	DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
20.05.22	DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
29.04.22	DGAP-CMS: QIAGEN N.V.: Release of a capital market information (EQS Group)
28.04.22	TDOC Q1 Results Lag Estimates, STRM Q4 Revenue Soars 100%, RGEN Trims Revenue Outlook (RTTNews)
27.04.22	QIAGEN N.V. Q1 Profit Rises; Increases Full Year Outlook (RTTNews)
13.04.22	DGAP-AFR: Qiagen N.V.: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act] (EQS Group)
13.04.22	DGAP-AFR: Qiagen N.V.: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß § 114, 115, 117 WpHG (EQS Group)
05.04.22	DGAP-DD: QIAGEN N.V. english (EQS Group)
05.04.22	DGAP-DD: QIAGEN N.V. english (EQS Group)
05.04.22	DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
05.04.22	DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
30.03.22	DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
30.03.22	DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
25.03.22	DGAP-DD: QIAGEN N.V. english (EQS Group)
25.03.22	DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
25.03.22	DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
18.03.22	DGAP-DD: QIAGEN N.V. english (EQS Group)
18.03.22	DGAP-DD: QIAGEN N.V. english (EQS Group)
18.03.22	DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
18.03.22	DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
14.03.22	DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
14.03.22	DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
14.03.22	DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
14.03.22	DGAP-CMS: QIAGEN N.V.: Release according to Article 50 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
07.03.22	DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
07.03.22	DGAP-PVR: QIAGEN N.V.: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution (EQS Group)
03.03.22	DGAP-DD: QIAGEN N.V. english (EQS Group)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	79.18	1.64 %	K V
CieFinRichemont	140.20	1.26 %	K V
Swiss Re	132.30	0.92 %	K V
Swiss Life Hldg	707.40	0.91 %	K V
Zurich Insur Gr	529.40	0.80 %	K V
Roche Hldg G	263.40	-0.57 %	K V
Kuehne+Nagel Int	200.00	-0.65 %	K V
Novartis	90.11	-0.75 %	K V
Givaudan	3’848.00	-0.95 %	K V
Lonza Grp	537.40	-1.29 %	K V

mehr

13.01.25		Synthetischer Aktienrückkauf: QIAGEN will Millionen an Aktionäre ausschütten - Aktie im Plus
08.01.25		QIAGEN verpartnert sich mit Genomics England - Aktie etwas schwächer
07.11.24		QIAGEN-Aktie springt hoch: QIAGEN überrascht positiv und hebt Gewinnprognose wieder an
11.10.24		QIAGEN-Aktie fällt: QIAGEN mit neuen Automationslösungen für Flüssigbiopsien
04.09.24		QIAGEN-Aktie schwächer: QIAGEN gibt finale Bedingungen für Wandelschuldverschreibungen bekannt
03.09.24		QIAGEN-Aktie verliert: QIAGEN startet Platzierung von Wandelschuldverschreibungen über 500 Millionen Dollar
12.06.24		QIAGEN-Aktie rot: 35 neue DNA-Nachweisverfahren für die Mikrobiomforschung: QIAGEN erweitert QIAcuity-Plattform
30.04.24		QIAGEN nach starken Zahlen auf Zielerreichungskurs - QIAGEN-Aktie dennoch knapp im Minus